WO2002062335A3 - Implantable device containing resorbable matrix material and anti-proliferative drugs for preventing or treating failure of hemodialysis vascular access and other vascular grafts - Google Patents

Implantable device containing resorbable matrix material and anti-proliferative drugs for preventing or treating failure of hemodialysis vascular access and other vascular grafts Download PDF

Info

Publication number
WO2002062335A3
WO2002062335A3 PCT/US2002/001375 US0201375W WO02062335A3 WO 2002062335 A3 WO2002062335 A3 WO 2002062335A3 US 0201375 W US0201375 W US 0201375W WO 02062335 A3 WO02062335 A3 WO 02062335A3
Authority
WO
WIPO (PCT)
Prior art keywords
vascular
preventing
matrix material
implantable device
hemodialysis
Prior art date
Application number
PCT/US2002/001375
Other languages
French (fr)
Other versions
WO2002062335A2 (en
Inventor
Sriram S Iyer
Nicholas N Kipshidze
Victor V Nikolaychik
Original Assignee
Vascular Therapies Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vascular Therapies Llc filed Critical Vascular Therapies Llc
Priority to AT02718844T priority Critical patent/ATE481097T1/en
Priority to BR0206464-2A priority patent/BR0206464A/en
Priority to NZ527046A priority patent/NZ527046A/en
Priority to MXPA03006315A priority patent/MXPA03006315A/en
Priority to DE60237671T priority patent/DE60237671D1/en
Priority to JP2002562342A priority patent/JP4584537B2/en
Priority to CA2434972A priority patent/CA2434972C/en
Priority to AU2002249958A priority patent/AU2002249958B2/en
Priority to EP02718844A priority patent/EP1351681B1/en
Priority to APAP/P/2003/002828A priority patent/AP2003002828A0/en
Publication of WO2002062335A2 publication Critical patent/WO2002062335A2/en
Publication of WO2002062335A3 publication Critical patent/WO2002062335A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/20—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/225—Fibrin; Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
    • A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3621—Extra-corporeal blood circuits
    • A61M1/3653—Interfaces between patient blood circulation and extra-corporal blood circuit
    • A61M1/3655—Arterio-venous shunts or fistulae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
    • A61M39/02—Access sites
    • A61M39/0247—Semi-permanent or permanent transcutaneous or percutaneous access sites to the inside of the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/204—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with nitrogen-containing functional groups, e.g. aminoxides, nitriles, guanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
    • A61M39/02—Access sites
    • A61M39/0247—Semi-permanent or permanent transcutaneous or percutaneous access sites to the inside of the body
    • A61M2039/0258—Semi-permanent or permanent transcutaneous or percutaneous access sites to the inside of the body for vascular access, e.g. blood stream access
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
    • A61M39/02—Access sites
    • A61M39/0247—Semi-permanent or permanent transcutaneous or percutaneous access sites to the inside of the body
    • A61M2039/0261—Means for anchoring port to the body, or ports having a special shape or being made of a specific material to allow easy implantation/integration in the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A61M2202/0468—Liquids non-physiological
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A61M2202/0468—Liquids non-physiological
    • A61M2202/0478—Heparin

Abstract

A therapeutic implant, apparatus and methods useful for preventing, suppressing (inhibiting) or treating failure of hemodialysis vascular access and other vascular grafts from outside the vascular or graft lumen and through the vascular wall (extravascularly or perivascularly). The implantable device contains resorbable matrix material (e.g. collagen, fibrin, chitosan) and antiproliverative agent(s), for instance3 Rapamycin, Paclitaxel, Tacrolimus etc. and other cell cycle inhibitor or similarly-functioning agents.
PCT/US2002/001375 2001-01-16 2002-01-16 Implantable device containing resorbable matrix material and anti-proliferative drugs for preventing or treating failure of hemodialysis vascular access and other vascular grafts WO2002062335A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
AT02718844T ATE481097T1 (en) 2001-01-16 2002-01-16 IMPLANTABLE DEVICE CONTAINING ABSORBABLE MATRIX MATERIAL AND ANTIPROLIFERATIVE ACTIVES FOR PREVENTING OR TREATING FAILURE OF VASCULAR HEMODIALYSIS APPROACHES AND OTHER VASCULAR TRANSPLANTS
BR0206464-2A BR0206464A (en) 2001-01-16 2002-01-16 Apparatus and processes for preventing or treating vascular access insufficiency for hemodialysis and other vascular grafts
NZ527046A NZ527046A (en) 2001-01-16 2002-01-16 A flexible cylindrical matrix material, preferably collagen with an antiproliferative agent preferably rapamycin dispersed throughout for implantation to be in contact with a vascular structure
MXPA03006315A MXPA03006315A (en) 2001-01-16 2002-01-16 Apparatus and methods for preventing or treating failure of hemodialysis vascular access and other vascular grafts.
DE60237671T DE60237671D1 (en) 2001-01-16 2002-01-16 IMPLANTABLE DEVICE CONTAINING RESORBABLE MATRIX MATERIALS AND ANTIPROLIFERATIVE ACTIVE SUBSTANCES FOR PREVENTING OR TREATING FAILURE OF VASCULAR HEMODIALYSIS ACCUMULATIONS AND OTHER VASCULAR TRANSPLANTS
JP2002562342A JP4584537B2 (en) 2001-01-16 2002-01-16 Implantable devices and methods for preventing or treating hemodialysis vascular access and other vascular graft dysfunctions, including resorbable matrix materials and antiproliferative agents
CA2434972A CA2434972C (en) 2001-01-16 2002-01-16 Implantable device containing resorbable matrix material and anti-proliferative drugs for preventing or treating failure of hemodialysis vascular access and other vascular grafts
AU2002249958A AU2002249958B2 (en) 2001-01-16 2002-01-16 Implantable device containing resorbable matrix material and anti-proliferative drugs for preventing or treating failure of hemodialysis vascular access and other vascular grafts
EP02718844A EP1351681B1 (en) 2001-01-16 2002-01-16 Implantable device containing resorbable matrix material and anti-proliferative drugs for preventing or treating failure of hemodialysis vascular access and other vascular grafts
APAP/P/2003/002828A AP2003002828A0 (en) 2001-01-16 2002-01-16 Implantable device containing resorbable matrix material and anti-proliferative drugs for preventing or treating failure of hemodialysis vascular access and other vascular grafts.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26213201P 2001-01-16 2001-01-16
US60/262,132 2001-01-16

Publications (2)

Publication Number Publication Date
WO2002062335A2 WO2002062335A2 (en) 2002-08-15
WO2002062335A3 true WO2002062335A3 (en) 2002-12-27

Family

ID=22996277

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/001375 WO2002062335A2 (en) 2001-01-16 2002-01-16 Implantable device containing resorbable matrix material and anti-proliferative drugs for preventing or treating failure of hemodialysis vascular access and other vascular grafts

Country Status (18)

Country Link
US (5) US6726923B2 (en)
EP (2) EP1351681B1 (en)
JP (2) JP4584537B2 (en)
CN (1) CN1492759A (en)
AP (1) AP2003002828A0 (en)
AT (1) ATE481097T1 (en)
AU (1) AU2002249958B2 (en)
BR (1) BR0206464A (en)
CA (1) CA2434972C (en)
CY (1) CY1119109T1 (en)
DE (1) DE60237671D1 (en)
DK (1) DK2314293T3 (en)
ES (1) ES2621652T3 (en)
MX (1) MXPA03006315A (en)
NZ (1) NZ527046A (en)
PT (1) PT2314293T (en)
RU (1) RU2345719C2 (en)
WO (1) WO2002062335A2 (en)

Families Citing this family (177)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7963997B2 (en) * 2002-07-19 2011-06-21 Kensey Nash Corporation Device for regeneration of articular cartilage and other tissue
US8697108B2 (en) * 1994-05-13 2014-04-15 Kensey Nash Corporation Method for making a porous polymeric material
US8795242B2 (en) * 1994-05-13 2014-08-05 Kensey Nash Corporation Resorbable polymeric device for localized drug delivery
DK0914102T3 (en) * 1996-05-24 2006-01-09 Angiotech Pharm Inc Preparations and methods for treating or preventing diseases of the body canals
US7959664B2 (en) * 1996-12-26 2011-06-14 Medinol, Ltd. Flat process of drug coating for stents
US7399480B2 (en) * 1997-09-26 2008-07-15 Abbott Laboratories Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices
US20030129215A1 (en) * 1998-09-24 2003-07-10 T-Ram, Inc. Medical devices containing rapamycin analogs
US6890546B2 (en) 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US8257726B2 (en) * 1997-09-26 2012-09-04 Abbott Laboratories Compositions, systems, kits, and methods of administering rapamycin analogs with paclitaxel using medical devices
US8057816B2 (en) * 1997-09-26 2011-11-15 Abbott Laboratories Compositions and methods of administering paclitaxel with other drugs using medical devices
US20020099438A1 (en) 1998-04-15 2002-07-25 Furst Joseph G. Irradiated stent coating
US20030040790A1 (en) * 1998-04-15 2003-02-27 Furst Joseph G. Stent coating
US7967855B2 (en) * 1998-07-27 2011-06-28 Icon Interventional Systems, Inc. Coated medical device
US8070796B2 (en) 1998-07-27 2011-12-06 Icon Interventional Systems, Inc. Thrombosis inhibiting graft
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
ATE343969T1 (en) † 2000-09-29 2006-11-15 Cordis Corp COATED MEDICAL DEVICES
US20050084514A1 (en) * 2000-11-06 2005-04-21 Afmedica, Inc. Combination drug therapy for reducing scar tissue formation
US20040241211A9 (en) * 2000-11-06 2004-12-02 Fischell Robert E. Devices and methods for reducing scar tissue formation
US6534693B2 (en) * 2000-11-06 2003-03-18 Afmedica, Inc. Surgically implanted devices having reduced scar tissue formation
US7763769B2 (en) 2001-02-16 2010-07-27 Kci Licensing, Inc. Biocompatible wound dressing
US7700819B2 (en) 2001-02-16 2010-04-20 Kci Licensing, Inc. Biocompatible wound dressing
US6808518B2 (en) 2001-09-28 2004-10-26 Ethicon, Inc. Methods and devices for treating diseased blood vessels
US8740973B2 (en) * 2001-10-26 2014-06-03 Icon Medical Corp. Polymer biodegradable medical device
US20030163144A1 (en) * 2002-02-28 2003-08-28 Weadock Kevin S. Sponge for creating an anastomosis between vessels
JP4265888B2 (en) * 2002-06-12 2009-05-20 株式会社リコー Image forming apparatus
US7361368B2 (en) * 2002-06-28 2008-04-22 Advanced Cardiovascular Systems, Inc. Device and method for combining a treatment agent and a gel
WO2004004598A2 (en) * 2002-07-02 2004-01-15 Polycord, Inc. Polymerized and modified rapamycins and their use in coating medical prostheses
JP2005532121A (en) * 2002-07-09 2005-10-27 イーバ コーポレイション Introduction device used in surgery and method of use thereof
US8016881B2 (en) * 2002-07-31 2011-09-13 Icon Interventional Systems, Inc. Sutures and surgical staples for anastamoses, wound closures, and surgical closures
US20050163821A1 (en) * 2002-08-02 2005-07-28 Hsing-Wen Sung Drug-eluting Biodegradable Stent and Delivery Means
US7438925B2 (en) 2002-08-26 2008-10-21 Biovention Holdings Ltd. Drug eluting coatings for medical implants
JP2005537854A (en) * 2002-09-06 2005-12-15 アボット・ラボラトリーズ Medical device comprising a hydration inhibitor
WO2004027027A2 (en) 2002-09-18 2004-04-01 Trustees Of The University Of Pennsylvania Method of inhibiting choroidal neovascularization
KR20050084599A (en) * 2002-09-26 2005-08-26 안지오테크 인터내셔날 아게 Perivascular wraps
AU2002953440A0 (en) * 2002-12-19 2003-01-09 Unisearch Limited A method of treating a stiffened vessel
MX349099B (en) * 2003-03-10 2017-07-11 Poet Res Inc Method for producing ethanol using raw starch.
US20050233030A1 (en) * 2004-03-10 2005-10-20 Broin And Associates, Inc. Methods and systems for producing ethanol using raw starch and fractionation
EP1460088A1 (en) 2003-03-21 2004-09-22 Biotest AG Humanized anti-CD4 antibody with immunosuppressive properties
US8821473B2 (en) 2003-04-15 2014-09-02 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
US8383158B2 (en) 2003-04-15 2013-02-26 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
WO2004112864A2 (en) * 2003-06-19 2004-12-29 Vascular Therapies Llc Medical devices and methods for regulating the tissue response to vascular closure devices
JP2007516740A (en) * 2003-11-10 2007-06-28 アンジオテック インターナショナル アーゲー Medical implants and scarring inhibitors
US7553326B2 (en) * 2003-11-24 2009-06-30 Sweet Richard M Method and apparatus for preventing dialysis graft intimal hyperplasia
US7211108B2 (en) * 2004-01-23 2007-05-01 Icon Medical Corp. Vascular grafts with amphiphilic block copolymer coatings
US20050239181A1 (en) * 2004-03-10 2005-10-27 Broin And Associates, Inc. Continuous process for producing ethanol using raw starch
US20070027523A1 (en) * 2004-03-19 2007-02-01 Toner John L Method of treating vascular disease at a bifurcated vessel using coated balloon
US8431145B2 (en) 2004-03-19 2013-04-30 Abbott Laboratories Multiple drug delivery from a balloon and a prosthesis
US20100030183A1 (en) * 2004-03-19 2010-02-04 Toner John L Method of treating vascular disease at a bifurcated vessel using a coated balloon
EP1735042B1 (en) * 2004-03-19 2011-11-23 Abbott Laboratories Multiple drug delivery from a balloon and a prosthesis
US7857767B2 (en) * 2004-04-19 2010-12-28 Invention Science Fund I, Llc Lumen-traveling device
KR100596218B1 (en) * 2004-06-10 2006-07-03 (주)액세스 플러스 Tube conntecting artery to vein for hemodialysis
US20060009839A1 (en) * 2004-07-12 2006-01-12 Scimed Life Systems, Inc. Composite vascular graft including bioactive agent coating and biodegradable sheath
WO2006017275A1 (en) 2004-07-13 2006-02-16 The University Of Tennessee Research Foundation Adhesive composition for carrying therapeutic agents as delivery vehicle on coatings applied to vascular grafts
US11207457B2 (en) 2004-08-27 2021-12-28 Edwards Lifesciences Corporation Device and method for establishing an artificial arterio-venous fistula
EP1791496B1 (en) 2004-08-31 2019-07-31 C.R. Bard, Inc. Self-sealing ptfe graft with kink resistance
US20060106406A1 (en) * 2004-09-27 2006-05-18 Judah Weinberger Methods and devices for extravascular intervention
US20060069426A1 (en) * 2004-09-27 2006-03-30 Weinberger Judah Z Methods and devices for extravascular intervention
US20060135970A1 (en) 2004-11-15 2006-06-22 Laurent Schaller Catheter-based tissue remodeling devices and methods
US7993738B2 (en) * 2004-11-30 2011-08-09 The Regents Of The University Of Michigan Modified porous materials and method of forming the same
WO2006062909A2 (en) * 2004-12-08 2006-06-15 Pervasis Therapeutics, Inc. Methods and compositions for enhancing vascular access
US20080118561A1 (en) * 2004-12-08 2008-05-22 Helen Marie Nugent Materials and Methods for Minimally-Invasive Administration of a Cell-Containing Flowable Composition
ES2564194T3 (en) 2005-02-09 2016-03-18 Santen Pharmaceutical Co., Ltd. Liquid formulations for the treatment of diseases or ailments
US8323333B2 (en) * 2005-03-03 2012-12-04 Icon Medical Corp. Fragile structure protective coating
US20060264914A1 (en) * 2005-03-03 2006-11-23 Icon Medical Corp. Metal alloys for medical devices
WO2006110197A2 (en) * 2005-03-03 2006-10-19 Icon Medical Corp. Polymer biodegradable medical device
US9107899B2 (en) 2005-03-03 2015-08-18 Icon Medical Corporation Metal alloys for medical devices
US20060201601A1 (en) * 2005-03-03 2006-09-14 Icon Interventional Systems, Inc. Flexible markers
US7540995B2 (en) 2005-03-03 2009-06-02 Icon Medical Corp. Process for forming an improved metal alloy stent
AU2006221046B2 (en) * 2005-03-03 2012-02-02 Icon Medical Corp. Improved metal alloys for medical device
EP1877004A4 (en) * 2005-03-23 2012-01-25 Abbott Lab Compositions and methods of administering rapamycin analogs using medical devices for long-term efficacy
US20080125745A1 (en) 2005-04-19 2008-05-29 Shubhayu Basu Methods and compositions for treating post-cardial infarction damage
US8828433B2 (en) * 2005-04-19 2014-09-09 Advanced Cardiovascular Systems, Inc. Hydrogel bioscaffoldings and biomedical device coatings
US9539410B2 (en) 2005-04-19 2017-01-10 Abbott Cardiovascular Systems Inc. Methods and compositions for treating post-cardial infarction damage
CA2605080A1 (en) * 2005-04-21 2006-11-02 Massachusetts Institute Of Technology Materials and methods for altering an immune response to exogenous and endogenous immunogens, including syngeneic and non-syngeneic cells, tissues or organs
US8333777B2 (en) 2005-04-22 2012-12-18 Benvenue Medical, Inc. Catheter-based tissue remodeling devices and methods
WO2006119386A2 (en) * 2005-05-02 2006-11-09 Broin And Associates, Inc. Methods and systems for producing ethanol using raw starch and fractionation
US8002738B2 (en) * 2005-05-17 2011-08-23 Boston Scientific Scimed, Inc. Self-adhering lesion formation apparatus and methods
JP2008543376A (en) * 2005-06-08 2008-12-04 シー・アール・バード・インコーポレーテッド Grafts and stents with inorganic biocompatible calcium salts
PT1890641T (en) 2005-06-17 2017-05-30 Bard Inc C R Vascular graft with kink resistance after clamping
SG195537A1 (en) 2005-06-21 2013-12-30 Shire Regenerative Medicine Inc Methods and compositions for enhancing vascular access
ES2574780T3 (en) * 2005-09-06 2016-06-22 C.R. Bard, Inc. Drug Release Graft
US7219021B2 (en) * 2005-09-13 2007-05-15 Honeywell International Inc. Multiple wireless sensors for dialysis application
US7919289B2 (en) 2005-10-10 2011-04-05 Poet Research, Inc. Methods and systems for producing ethanol using raw starch and selecting plant material
WO2007046935A2 (en) * 2005-10-14 2007-04-26 Abbott Laboratories Compositions, systems, kits, and methods of administering rapamycin analogs with paclitaxel using medical devices
CA2626598A1 (en) 2005-11-09 2007-05-18 C.R. Bard Inc. Grafts and stent grafts having a radiopaque marker
US20080317814A1 (en) * 2005-11-17 2008-12-25 Access Plus Co., Ltd. Tube for Connecting Marteriovenous and Interposition for Medical Operation
US20100204783A1 (en) * 2005-12-06 2010-08-12 Helen Marie Nugent Methods and compositions for enhancing vascular access
BRPI0600275A (en) * 2006-01-03 2007-10-02 Brz Biotecnologia Ltda Coronary prosthesis releasing drug composition for prevention and treatment of restenosis and manufacturing process
KR20140093764A (en) 2006-02-09 2014-07-28 산텐 세이야꾸 가부시키가이샤 Stable formulations, and methods of their preparation and use
US8828077B2 (en) * 2006-03-15 2014-09-09 Medinol Ltd. Flat process of preparing drug eluting stents
DK2001466T3 (en) 2006-03-23 2016-02-29 Santen Pharmaceutical Co Ltd LOW-DOSAGE RAPAMYCINE FOR TREATMENT OF VASCULAR PERMEABILITY-RELATED DISEASES
US7818084B2 (en) * 2006-06-16 2010-10-19 The Invention Science Fund, I, LLC Methods and systems for making a blood vessel sleeve
US20080133040A1 (en) * 2006-06-16 2008-06-05 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for specifying a blood vessel sleeve
US8163003B2 (en) * 2006-06-16 2012-04-24 The Invention Science Fund I, Llc Active blood vessel sleeve methods and systems
US8551155B2 (en) * 2006-06-16 2013-10-08 The Invention Science Fund I, Llc Stent customization system and method
US8147537B2 (en) * 2006-06-16 2012-04-03 The Invention Science Fund I, Llc Rapid-prototyped custom-fitted blood vessel sleeve
US20080172073A1 (en) * 2006-06-16 2008-07-17 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Active blood vessel sleeve
US20090024152A1 (en) * 2007-07-17 2009-01-22 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Custom-fitted blood vessel sleeve
US8550344B2 (en) * 2006-06-16 2013-10-08 The Invention Science Fund I, Llc Specialty stents with flow control features or the like
US8095382B2 (en) * 2006-06-16 2012-01-10 The Invention Science Fund I, Llc Methods and systems for specifying a blood vessel sleeve
US8478437B2 (en) 2006-06-16 2013-07-02 The Invention Science Fund I, Llc Methods and systems for making a blood vessel sleeve
US7722665B2 (en) * 2006-07-07 2010-05-25 Graft Technologies, Inc. System and method for providing a graft in a vascular environment
WO2008008291A2 (en) * 2006-07-13 2008-01-17 Icon Medical Corp. Stent
US20080039362A1 (en) * 2006-08-09 2008-02-14 Afmedica, Inc. Combination drug therapy for reducing scar tissue formation
US20080077070A1 (en) * 2006-08-10 2008-03-27 Kopia Gregory A Arteriovenous shunt
US9242005B1 (en) 2006-08-21 2016-01-26 Abbott Cardiovascular Systems Inc. Pro-healing agent formulation compositions, methods and treatments
US20080085293A1 (en) * 2006-08-22 2008-04-10 Jenchen Yang Drug eluting stent and therapeutic methods using c-Jun N-terminal kinase inhibitor
US8980323B2 (en) * 2006-08-29 2015-03-17 Fujifilm Corporation Hydrophilic matrix containing poorly water-soluble compound and method for producing the same
US9198749B2 (en) 2006-10-12 2015-12-01 C. R. Bard, Inc. Vascular grafts with multiple channels and methods for making
JP5372764B2 (en) * 2006-11-07 2013-12-18 シャイア リジェネラティブ メディシン， インコーポレイテッド Materials and methods for the treatment and management of angiogenesis-related diseases
US9005672B2 (en) 2006-11-17 2015-04-14 Abbott Cardiovascular Systems Inc. Methods of modifying myocardial infarction expansion
US8741326B2 (en) * 2006-11-17 2014-06-03 Abbott Cardiovascular Systems Inc. Modified two-component gelation systems, methods of use and methods of manufacture
US8192760B2 (en) 2006-12-04 2012-06-05 Abbott Cardiovascular Systems Inc. Methods and compositions for treating tissue using silk proteins
US8177798B2 (en) 2006-12-05 2012-05-15 Tyco Healthcare Group Lp Adhesive coated stent and insertion instrument
WO2008156705A1 (en) * 2007-06-13 2008-12-24 Pervasis Therapeutics, Inc. Methods and devices for minimally-invasive delivery of cell-containing flowable compositions
US9504469B2 (en) 2007-06-18 2016-11-29 Asfora Ip, Llc Vascular anastomosis device and method
US10004507B2 (en) 2007-06-18 2018-06-26 Asfora Ip, Llc Vascular anastomosis device and method
US8361092B1 (en) 2007-06-18 2013-01-29 Wilson T. Asfora Vascular anastomosis device and method
US8721711B2 (en) * 2007-06-20 2014-05-13 Oregon Health & Science University Graft having microporous membrane for uniform fluid infusion
WO2009073782A2 (en) * 2007-12-04 2009-06-11 Ams Research Corporation Apparatus and methods for treatment of pathologic proliferative conditions of uterine tissue
WO2009079388A2 (en) * 2007-12-14 2009-06-25 Oregon Health & Science University Drug delivery cuff
US8741840B2 (en) 2008-02-13 2014-06-03 Washington University BMP-7 for use in treating neointimal hyperplasia
CN102105185A (en) * 2008-02-26 2011-06-22 大卫·张 Method and apparatus for vascular access
JP5604311B2 (en) 2008-03-13 2014-10-08 バイオテスト・アクチエンゲゼルシヤフト Disease treatment agent
JP5795167B2 (en) 2008-03-13 2015-10-14 バイオテスト・アクチエンゲゼルシヤフト Disease treatment agent
SG190598A1 (en) 2008-03-13 2013-06-28 Biotest Ag Agent for treating disease
US20090264906A1 (en) * 2008-04-22 2009-10-22 Medtronic Vascular, Inc. Cuff Device
JP2012504110A (en) * 2008-09-29 2012-02-16 バイオテスト・アクチエンゲゼルシヤフト Disease treatment composition
KR101034654B1 (en) * 2009-01-15 2011-05-16 성균관대학교산학협력단 Bioactive material coating method
WO2010102060A2 (en) * 2009-03-03 2010-09-10 Poet Research, Inc. System for pre-treatment of biomass for the production of ethanol
US8450094B1 (en) 2009-03-03 2013-05-28 Poet Research, Inc. System for management of yeast to facilitate the production of ethanol
EP2403954B1 (en) 2009-03-03 2015-04-22 POET Research, Inc. Method for fermentation of biomass for the production of ethanol
US9068206B1 (en) 2009-03-03 2015-06-30 Poet Research, Inc. System for treatment of biomass to facilitate the production of ethanol
US20100233266A1 (en) 2009-03-13 2010-09-16 Cleek Robert L Articles and methods of treating vascular conditions
EP3138517B1 (en) * 2009-04-20 2019-06-12 Rox Medical, Inc. Device for establishing an artificial arterio-venous fistula
WO2011006067A1 (en) * 2009-07-09 2011-01-13 Ams Research Corporation Apparatus and methods of treatment of pathologic proliferative conditions uterine tissue
WO2011040652A1 (en) * 2009-09-29 2011-04-07 주식회사 엠아이텍 Implant tube and method for coating same
AU2010324536B2 (en) 2009-11-27 2016-03-03 Stephen Anthony Livesey A method of inducing cellular growth and materials for use therewith
GB0920944D0 (en) 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
US20110144577A1 (en) * 2009-12-11 2011-06-16 John Stankus Hydrophilic coatings with tunable composition for drug coated balloon
US8480620B2 (en) * 2009-12-11 2013-07-09 Abbott Cardiovascular Systems Inc. Coatings with tunable solubility profile for drug-coated balloon
US8951595B2 (en) * 2009-12-11 2015-02-10 Abbott Cardiovascular Systems Inc. Coatings with tunable molecular architecture for drug-coated balloon
WO2011072398A1 (en) 2009-12-18 2011-06-23 Interface Biologics, Inc. Local delivery of drugs from self assembled coatings
JP2011130989A (en) * 2009-12-25 2011-07-07 Japan Health Science Foundation Antithrombogenic modifier, medical instrument and porous collagen
CA2786282C (en) * 2009-12-30 2020-09-08 Caliber Therapeutics, Inc. Balloon catheter systems for delivery of dry drug delivery vesicles to a vessel in the body
US8399044B2 (en) * 2010-01-21 2013-03-19 Snu R And Db Foundation Method for coating medication on medical article
JP6172704B2 (en) * 2010-01-27 2017-08-02 バスキュラー・セラピーズ・インコーポレイテッド Apparatus and method for prevention of stenosis at the site of anastomosis
US8974519B2 (en) 2010-02-19 2015-03-10 Cardiovascular Systems, Inc. Therapeutic agent delivery system, device and method for localized application of therapeutic substances to a biological conduit
US8398916B2 (en) 2010-03-04 2013-03-19 Icon Medical Corp. Method for forming a tubular medical device
ES2793478T3 (en) * 2010-03-09 2020-11-16 Solinas Medical Inc Automatic closing devices
IT1400232B1 (en) * 2010-05-07 2013-05-24 Advance Holdings Ltd PHARMACEUTICAL COMPOSITION TOPICAL COMPARING EPARIN
CN109172809A (en) 2011-04-28 2019-01-11 阿布拉科斯生物科学有限公司 The intravascular delivering and its application of Nanoparticulate compositions
US10350431B2 (en) * 2011-04-28 2019-07-16 Gt Medical Technologies, Inc. Customizable radioactive carriers and loading system
WO2012159169A1 (en) * 2011-05-26 2012-11-29 Kathy Traianedes A method of ex vivo cellular growth
US8577693B2 (en) 2011-07-13 2013-11-05 The Invention Science Fund I, Llc Specialty stents with flow control features or the like
US9433722B2 (en) * 2011-08-09 2016-09-06 Abbott Cardiovascular Systems Inc. Vascular shield and delivery system
RS61726B1 (en) * 2012-01-09 2021-05-31 Innocoll Pharm Ltd A modified collagen
US20130303983A1 (en) * 2012-05-09 2013-11-14 Cook Medical Technologies Llc Coated medical devices including a water-insoluble therapeutic agent
AU2013338051C1 (en) 2012-10-29 2017-08-10 Ariste Medical, Llc. Polymer coating compositions and coated products
WO2014127278A2 (en) * 2013-02-18 2014-08-21 Elutin, Inc. Site specific drug delivery wraps, systems and methods of use thereof
US9492683B2 (en) 2013-03-15 2016-11-15 Gammatile Llc Dosimetrically customizable brachytherapy carriers and methods thereof in the treatment of tumors
US20150119908A1 (en) * 2013-10-25 2015-04-30 Abbott Cardiovascular Systems Inc. Extravascular devices supporting an arteriovenous fistula
US20150119976A1 (en) * 2013-10-29 2015-04-30 Abbott Cardiovascular Systems Inc. Extravascular device for limiting blood flow adjacent an arteriovenous fistula
US9687239B2 (en) 2014-04-15 2017-06-27 Abbott Cardiovascular Systems Inc. Intravascular devices supporting an arteriovenous fistula
GB2528421B (en) 2014-04-22 2016-12-14 Ariste Medical Inc Methods and processes for application of drug delivery polymeric coatings
BR112016030273A2 (en) 2014-06-24 2017-08-22 Icon Medical Corp MEDICAL DEVICE AND METHOD FOR FORMING SAID DEVICE
US20160193390A1 (en) * 2015-01-05 2016-07-07 Wisconsin Alumni Research Foundation Perivascular Delivery System And Method
CN107360713A (en) * 2015-01-26 2017-11-17 墨卡托医疗系统公司 For suppressing the method and system of vascular inflammation
US9821174B1 (en) 2015-02-06 2017-11-21 Gammatile Llc Radioactive implant planning system and placement guide system
US9907680B2 (en) * 2015-04-10 2018-03-06 Cook Medical Technologies Llc Sliding fenestration
US11766506B2 (en) 2016-03-04 2023-09-26 Mirus Llc Stent device for spinal fusion
US10888710B1 (en) 2016-11-29 2021-01-12 Gt Medical Technologies, Inc. Transparent loading apparatus
EP3796948A4 (en) 2018-05-22 2022-03-02 Interface Biologics Inc. Compositions and methods for delivering drugs to a vessel wall
DE102018127200B3 (en) * 2018-10-31 2019-07-25 Andreas Haas IMPLANT TO SUBCUTANEOUS IMPLANT
CN111012409A (en) * 2019-12-03 2020-04-17 王超 Auxiliary tee joint for reconstruction of blood transportation of frontal branch of superficial temporal artery and cerebral artery cortex and use method
CN114259607B (en) * 2021-12-28 2023-01-24 宇航 Preparation method of stent

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993023013A1 (en) * 1992-05-20 1993-11-25 New England Deaconess Hospital Extravascular system for infusion of soluble substances
US5486524A (en) * 1992-10-13 1996-01-23 American Home Products Corporation Carbamates of rapamycin
US5527532A (en) * 1989-11-13 1996-06-18 President And Fellows Of Harvard College Extraluminal regulation of the growth and repair of tubular structures in vivo
US5766584A (en) * 1995-06-02 1998-06-16 Massachusetts Institute Of Technology Inhibition of vascular smooth muscle cell proliferation with implanted matrix containing vascular endothelial cells
US6328762B1 (en) * 1999-04-27 2001-12-11 Sulzer Biologics, Inc. Prosthetic grafts
WO2002036054A1 (en) * 2000-11-06 2002-05-10 Afmedica, Inc. Surgically implanted devices having reduced scar tissue

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU471719A3 (en) 1969-07-19 1975-05-25 Шеринг Аг (Фирма) The method of obtaining nitrofurylaminoalkoxypyrimidine
US3797485A (en) 1971-03-26 1974-03-19 Alza Corp Novel drug delivery device for administering drug into blood circulation in blood vessel
US4391797A (en) 1977-01-05 1983-07-05 The Children's Hospital Medical Center Systems for the controlled release of macromolecules
US4164559A (en) 1977-09-21 1979-08-14 Cornell Research Foundation, Inc. Collagen drug delivery device
US4409332A (en) 1982-01-12 1983-10-11 Jefferies Steven R Collagen-enzyme conjugates that exhibit no inflammatory response and method for making the same
US4677120A (en) 1985-07-31 1987-06-30 Molecular Design International Topical prodrugs for treatment of acne and skin diseases
US4863457A (en) 1986-11-24 1989-09-05 Lee David A Drug delivery device
US4889842A (en) 1987-03-03 1989-12-26 Morris Randall E Concanavalin A dimers as therapeutic agents
US4885311A (en) 1987-06-29 1989-12-05 Molecular Design International Topical transretinoids for treatment of acne and skin diseases
US5124356A (en) 1987-06-29 1992-06-23 Molecular Design International, Inc. Dermal uses of trans-retinoids for the treatment of photoaging
US4994491A (en) 1988-12-14 1991-02-19 Molecular Design International Dermal uses of trans-retinoids for the treatment of cancer
US4840940A (en) 1987-10-21 1989-06-20 Sottiurai Vikrom S Method for reducing the occurrence of distal anastomotic intimal hyperplasia using fractionated heparin
US5157049A (en) 1988-03-07 1992-10-20 The United States Of America As Represented By The Department Of Health & Human Services Method of treating cancers sensitive to treatment with water soluble derivatives of taxol
US5100668A (en) 1988-06-14 1992-03-31 Massachusetts Institute Of Technology Controlled release systems containing heparin and growth factors
US5074869A (en) * 1988-09-26 1991-12-24 Daicoff George R Vascular occlusion device
US5049584A (en) 1988-12-14 1991-09-17 Molecular Design International Dermal uses of cis-retinoids for the treatment of cancer
US5223269A (en) 1989-08-31 1993-06-29 Andrejs Liepins Methods and composition for the treatment of hypertension
US6326017B1 (en) 1989-10-02 2001-12-04 University Of Washington Methods for the localized delivery of agents to blood vessels
WO1991007154A1 (en) 1989-11-13 1991-05-30 President And Fellows Of Harvard College EXTRALUMINAL REGULATION OF THE GROWTH AND REPAIR OF TUBULAR STRUCTURES ιIN VIVO
US5540928A (en) 1991-02-27 1996-07-30 President And Fellows Of Harvard College Extraluminal regulation of the growth and repair of tubular structures in vivo
US5138051A (en) 1991-08-07 1992-08-11 American Home Products Corporation Rapamycin analogs as immunosuppressants and antifungals
EP0558697A1 (en) 1991-06-28 1993-09-08 Massachusetts Institute Of Technology Localized oligonucleotide therapy
US5169851A (en) 1991-08-07 1992-12-08 American Home Products Corporation Rapamycin analog as immunosuppressants and antifungals
US5202332A (en) 1991-08-07 1993-04-13 American Home Products Corporation Rapamycin analog as immunosuppressant
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
EP0539237A1 (en) 1991-10-25 1993-04-28 Cook Incorporated Expandable transluminal graft prosthesis for repair of aneurysm and method for implanting
US5516781A (en) 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
IT1254915B (en) * 1992-04-24 1995-10-11 Gloria Cristalli ADENOSINE DERIVATIVES FOR ACTIVITY A2 AGONIST
US5288711A (en) 1992-04-28 1994-02-22 American Home Products Corporation Method of treating hyperproliferative vascular disease
US5283257A (en) 1992-07-10 1994-02-01 The Board Of Trustees Of The Leland Stanford Junior University Method of treating hyperproliferative vascular disease
CA2086874E (en) 1992-08-03 2000-01-04 Renzo Mauro Canetta Methods for administration of taxol
US6306421B1 (en) 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
CA2092271C (en) 1993-03-09 2009-10-13 Eddie Reed Use of g-csf for treating taxol side-effects
US5703247A (en) 1993-03-11 1997-12-30 Virginia Tech Intellectual Properties, Inc. 2-Debenzoyl-2-acyl taxol derivatives and methods for making same
US5571800A (en) 1993-05-17 1996-11-05 Azura, Inc. Method for inhibiting allograft rejection by the administration of 6-azauridine or its triacetate derivative
EP0982302B1 (en) 1993-06-11 2004-04-14 PHARMACIA & UPJOHN COMPANY Delta 6,7-taxols antineoplastic use and pharmaceutical compositions containing them
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
PT711158E (en) 1993-07-29 2004-04-30 Us Gov Health & Human Serv METHOD FOR TREATING ATHEROSCLEROSIS OR RESTENING USING A MICROTUBLE STABILIZING AGENT
US6323184B1 (en) 1993-10-15 2001-11-27 Thomas Jefferson University Arteriovenous and venous graft treatments: methods and compositions
US5519042A (en) 1994-01-13 1996-05-21 Hoechst Aktiengesellschaft Method of treating hyperproliferative vascular disease
IL127598A (en) 1994-01-28 2003-04-10 Upjohn Co Process for preparing isotaxol analogs
EP0698396B1 (en) 1994-08-12 2001-12-12 Meadox Medicals, Inc. Vascular graft impregnated with a heparin-containing collagen sealant
US5660873A (en) 1994-09-09 1997-08-26 Bioseal, Limited Liability Corporaton Coating intraluminal stents
US5616680A (en) * 1994-10-04 1997-04-01 Hoechst Celanese Corporation Process for producing liquid crystal polymer
US5837728A (en) 1995-01-27 1998-11-17 Molecular Design International 9-cis retinoic acid esters and amides and uses thereof
US5780653A (en) 1995-06-07 1998-07-14 Vivorx Pharmaceuticals, Inc. Nitrophenyl, 10-deacetylated substituted taxol derivatives as dual functional cytotoxic/radiosensitizers
AU716005B2 (en) 1995-06-07 2000-02-17 Cook Medical Technologies Llc Implantable medical device
AU7360396A (en) 1995-09-11 1997-04-01 Enzymed, Inc. Biocatalytic methods for synthesizing and identifying biologically active compounds
US5795286A (en) * 1996-08-15 1998-08-18 Cathco, Inc. Radioisotope impregnated sheet of biocompatible material for preventing scar tissue formation
DE69725592T2 (en) 1996-08-23 2004-08-05 Cook Biotech, Inc., West Lafayette METHOD FOR OBTAINING A SUITABLE COLLAGEN-BASED MATRIX FROM SUBMUKOSA TISSUE
US6273913B1 (en) 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
US6090996A (en) 1997-08-04 2000-07-18 Collagen Matrix, Inc. Implant matrix
US6015815A (en) 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
US6117166A (en) 1997-10-27 2000-09-12 Winston; Thomas R. Apparatus and methods for grafting blood vessel tissue
US6224794B1 (en) 1998-05-06 2001-05-01 Angiotech Pharmaceuticals, Inc. Methods for microsphere production
US6091980A (en) 1998-05-12 2000-07-18 Massachusetts Institute Of Technology Stent slip sensing system and method
US6179858B1 (en) 1998-05-12 2001-01-30 Massachusetts Institute Of Technology Stent expansion and apposition sensing
ATE275417T1 (en) * 1998-10-26 2004-09-15 Ludwig Inst Cancer Res USE OF VEGF-C AND VEGF-D GENES OR PROTEINS TO PREVENT RESTENOSIS
DE19849589C1 (en) 1998-10-27 2000-06-15 Glatt Process Technology Gmbh Fibrin tissue adhesive formulation and process for its manufacture
US6333347B1 (en) 1999-01-29 2001-12-25 Angiotech Pharmaceuticals & Advanced Research Tech Intrapericardial delivery of anti-microtubule agents
US6391333B1 (en) 1999-04-14 2002-05-21 Collagen Matrix, Inc. Oriented biopolymeric membrane
JP2003520830A (en) 2000-01-25 2003-07-08 エドワーズ ライフサイエンシーズ コーポレイション Delivery system for treatment of restenosis and anastomotic intimal hyperplasia
US6746773B2 (en) 2000-09-29 2004-06-08 Ethicon, Inc. Coatings for medical devices
PE20091074A1 (en) 2007-12-13 2009-07-26 Bayer Healthcare Ag TRIAZOLOTRIAZINES AND TRIAZOLOPYRAZINES AND THEIR USE

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5527532A (en) * 1989-11-13 1996-06-18 President And Fellows Of Harvard College Extraluminal regulation of the growth and repair of tubular structures in vivo
WO1993023013A1 (en) * 1992-05-20 1993-11-25 New England Deaconess Hospital Extravascular system for infusion of soluble substances
US5486524A (en) * 1992-10-13 1996-01-23 American Home Products Corporation Carbamates of rapamycin
US5766584A (en) * 1995-06-02 1998-06-16 Massachusetts Institute Of Technology Inhibition of vascular smooth muscle cell proliferation with implanted matrix containing vascular endothelial cells
US6328762B1 (en) * 1999-04-27 2001-12-11 Sulzer Biologics, Inc. Prosthetic grafts
WO2002036054A1 (en) * 2000-11-06 2002-05-10 Afmedica, Inc. Surgically implanted devices having reduced scar tissue

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EDELMAN^A E R ET AL: "Perivascular graft heparin delivery using biodegradable polymer wraps", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 21, no. 22, 15 November 2000 (2000-11-15), pages 2279 - 2286, XP004210285, ISSN: 0142-9612 *
HIRIGOYEN M B ET AL: "Periadventitial delivery of heparin in the prevention of microvenous thrombosis.", JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY: OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION OF ORAL AND MAXILLOFACIAL SURGEONS. UNITED STATES SEP 1996, vol. 54, no. 9, September 1996 (1996-09-01), pages 1097 - 1102, XP001097380, ISSN: 0278-2391 *

Also Published As

Publication number Publication date
US20040197409A1 (en) 2004-10-07
US6726923B2 (en) 2004-04-27
US7807191B2 (en) 2010-10-05
DK2314293T3 (en) 2017-04-18
JP2009119257A (en) 2009-06-04
CY1119109T1 (en) 2018-02-14
US8858982B2 (en) 2014-10-14
JP2004523537A (en) 2004-08-05
MXPA03006315A (en) 2004-12-03
EP2314293A1 (en) 2011-04-27
CA2434972C (en) 2010-06-08
JP5748389B2 (en) 2015-07-15
CN1492759A (en) 2004-04-28
ES2621652T3 (en) 2017-07-04
AP2003002828A0 (en) 2003-09-30
US20150209334A1 (en) 2015-07-30
AU2002249958B2 (en) 2007-11-08
CA2434972A1 (en) 2002-08-15
RU2003125357A (en) 2005-03-10
RU2345719C2 (en) 2009-02-10
US10272073B2 (en) 2019-04-30
EP1351681B1 (en) 2010-09-15
WO2002062335A2 (en) 2002-08-15
US20190201383A1 (en) 2019-07-04
EP2314293B1 (en) 2017-01-04
ATE481097T1 (en) 2010-10-15
BR0206464A (en) 2005-01-18
NZ527046A (en) 2005-06-24
JP4584537B2 (en) 2010-11-24
US20030113359A1 (en) 2003-06-19
EP1351681A2 (en) 2003-10-15
US20080091263A1 (en) 2008-04-17
PT2314293T (en) 2017-04-11
DE60237671D1 (en) 2010-10-28

Similar Documents

Publication Publication Date Title
WO2002062335A3 (en) Implantable device containing resorbable matrix material and anti-proliferative drugs for preventing or treating failure of hemodialysis vascular access and other vascular grafts
WO2002047731A3 (en) Drug delivery compositions and coated medical devices
CA2490170A1 (en) Local vascular delivery of trichostatin a alone or in combination with sirolimus to prevent restenosis following vascular injury
EP1568387A3 (en) Radioprotective compound coating for medical devices
ATE475438T1 (en) LOCAL, VASCULAR ADMINISTRATION OF ETOPOSIDE IN COMBINATION WITH RAPAMYCIN TO PREVENT RESTENOSIS AFTER VASCULAR INJURY
MXPA03004512A (en) Coated medical devices for the prevention and treatment of vascular disease.
WO2002056912A3 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
TW200730152A (en) Drug delivery systems for the prevention and treatment of vascular diseases
WO2004000379A8 (en) Stent coatings with sustained drug release rate
ATE529068T1 (en) MULTI-LAYER COATED STENT FOR THE CONTROLLED RELEASE OF ACTIVE SUBSTANCES AND METHOD FOR THE PRODUCTION THEREOF
WO2004028583A3 (en) Perivascular wraps
WO2001087342A3 (en) Delivery devices for treatment of vascular disease
WO2003009777A3 (en) Delivery of therapeutic capable agents
WO2004050140A3 (en) Medical devices for delivery of therapeutic agents
WO2005011734A3 (en) Composition of a vegf antagonist and an anti-proliferative agent and its use for the treatment of cancer
CA2467797A1 (en) Increased biocompatibility of implantable medical devices
WO2004028570A3 (en) A method for treating severe tinnitus
WO2006047378A3 (en) Biocompatible and hemocompatible amphiphilic coatings for drug deliver
EP1426076A3 (en) Sustained release coating for medical devices
WO2006068841A3 (en) Hemostasis cuff for catheter securement
ATE476205T1 (en) IMPLANTABLE VASCULAR DEVICE FOR DELIVERING TOPOTECAN IN COMBINATION WITH RAPAMYCIN
CA2408754A1 (en) Delivery devices for treatment of vascular disease
WO2005055953A3 (en) Methods of preventing and treating gastrointestinal dysfunction
WO2004009773A3 (en) Methods and compositions for activating or inhibiting vegf-d and vegf-c
WO2003011250A8 (en) Heparin stent

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/006315

Country of ref document: MX

Ref document number: 2434972

Country of ref document: CA

Ref document number: 2002249958

Country of ref document: AU

Ref document number: 903/KOLNP/2003

Country of ref document: IN

Ref document number: 00902/KOLNP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2002562342

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 527046

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2002718844

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 02805296X

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2002718844

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 527046

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 527046

Country of ref document: NZ